首页 > 最新文献

Problemy endokrinologii最新文献

英文 中文
[Iodine status of the population in the WHO European Region (an abridged translation of selected sections of the WHO European report)]. [世卫组织欧洲区域人口碘状况(世卫组织欧洲报告部分节选译文)]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13611
G A Gerasimov

This review is an abridged translation of selected chapters of the report "Prevention and control of iodine deficiency in the WHO European Region: adapting to changes in diet and lifestyle", published by the WHO Regional Office for Europe and the Iodine Global Network (IGN) in 2024. Iodine deficiency, especially mild iodine deficiency, remains a widespread problem in the WHO European Region. Since the last WHO report on iodine deficiency in the Region 15 years ago, much new data on iodine status has become available, especially for vulnerable populations. This review presents data on the iodine status of the population in 53 WHO European Member States (and Kosovo), the adverse effects of mild iodine deficiency and the effectiveness of salt iodization in preventing iodine deficiency. Mainly due to progress in salt iodization, the number of countries with iodine deficiency has decreased from 23 in 2003 to 2 in 2023. Mandatory salt iodization ensures adequate iodine intake in all population groups, with the exception of a few countries where these programs are poorly implemented. The positive cost-benefit ratio for preventing mild iodine deficiency in the European Region is plausible given the high prevalence of thyroid disease and the low cost of salt fortification programs.

本综述是世卫组织欧洲区域办事处和碘全球网络(IGN)于2024年出版的《世卫组织欧洲区域预防和控制碘缺乏症:适应饮食和生活方式的变化》报告部分章节的节略翻译。缺碘,特别是轻度缺碘,仍然是世卫组织欧洲区域普遍存在的问题。自15年前世卫组织上一份关于该区域碘缺乏症的报告以来,已经获得了许多关于碘状况的新数据,特别是关于脆弱人群的数据。本综述介绍了53个世卫组织欧洲成员国(和科索沃)人口碘状况的数据、轻度碘缺乏的不利影响以及盐加碘预防碘缺乏的有效性。主要由于食盐加碘方面的进展,缺碘国家的数量已从2003年的23个减少到2023年的2个。强制性食盐加碘可确保所有人群摄入足够的碘,只有少数国家的项目执行不力。鉴于甲状腺疾病的高患病率和盐强化计划的低成本,预防欧洲地区轻度碘缺乏症的正成本效益比似乎是合理的。
{"title":"[Iodine status of the population in the WHO European Region (an abridged translation of selected sections of the WHO European report)].","authors":"G A Gerasimov","doi":"10.14341/probl13611","DOIUrl":"10.14341/probl13611","url":null,"abstract":"<p><p>This review is an abridged translation of selected chapters of the report \"Prevention and control of iodine deficiency in the WHO European Region: adapting to changes in diet and lifestyle\", published by the WHO Regional Office for Europe and the Iodine Global Network (IGN) in 2024. Iodine deficiency, especially mild iodine deficiency, remains a widespread problem in the WHO European Region. Since the last WHO report on iodine deficiency in the Region 15 years ago, much new data on iodine status has become available, especially for vulnerable populations. This review presents data on the iodine status of the population in 53 WHO European Member States (and Kosovo), the adverse effects of mild iodine deficiency and the effectiveness of salt iodization in preventing iodine deficiency. Mainly due to progress in salt iodization, the number of countries with iodine deficiency has decreased from 23 in 2003 to 2 in 2023. Mandatory salt iodization ensures adequate iodine intake in all population groups, with the exception of a few countries where these programs are poorly implemented. The positive cost-benefit ratio for preventing mild iodine deficiency in the European Region is plausible given the high prevalence of thyroid disease and the low cost of salt fortification programs.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"29-38"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The History of the Development of Radioiodine Therapy in Russia]. [俄罗斯放射性碘治疗发展的历史]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13633
M S Sheremeta, M V Reinberg, K V Frolov, G А Melnichenko

This article traces the history of the development of radioiodine therapy (RIT) as one of the leading methods for treating thyroid disorders. The relevance of the topic is determined by the high efficacy of RIT in managing thyrotoxicosis and differentiated thyroid cancer, as well as the ongoing efforts to refine dosimetric strategies and molecular imaging techniques. Based on a systematic review of historical publications and monographs from 1923 to 2022, the study analyzes key milestones in the clinical implementation of iodine-131 - from the pioneering experiments of Hertz and Seidlin in the United States in 1937 to the widespread adoption of the method in the USSR beginning in the 1950s and its subsequent advancement at the National Medical Research Center for Endocrinology of the Ministry of Health of the Russian Federation. The reviewed literature highlights the significant contributions of Russian researchers to the formation of personalized theranostic approaches and underscores the need for further improvement in planning methods, dynamic treatment monitoring, and the broader expansion of radionuclide therapies for thyroid diseases.

本文追溯了放射性碘疗法(RIT)作为治疗甲状腺疾病的主要方法之一的发展历史。该主题的相关性取决于RIT在治疗甲状腺毒症和分化型甲状腺癌方面的高疗效,以及不断改进剂量学策略和分子成像技术的努力。基于对1923年至2022年的历史出版物和专著的系统回顾,该研究分析了碘-131临床实施的关键里程碑——从1937年美国赫兹和塞德林的开创性实验到20世纪50年代开始在苏联广泛采用该方法,以及随后在俄罗斯联邦卫生部国家内分泌医学研究中心的进展。回顾的文献强调了俄罗斯研究人员对个性化治疗方法形成的重要贡献,并强调了进一步改进计划方法、动态治疗监测和更广泛地扩展放射性核素治疗甲状腺疾病的必要性。
{"title":"[The History of the Development of Radioiodine Therapy in Russia].","authors":"M S Sheremeta, M V Reinberg, K V Frolov, G А Melnichenko","doi":"10.14341/probl13633","DOIUrl":"10.14341/probl13633","url":null,"abstract":"<p><p>This article traces the history of the development of radioiodine therapy (RIT) as one of the leading methods for treating thyroid disorders. The relevance of the topic is determined by the high efficacy of RIT in managing thyrotoxicosis and differentiated thyroid cancer, as well as the ongoing efforts to refine dosimetric strategies and molecular imaging techniques. Based on a systematic review of historical publications and monographs from 1923 to 2022, the study analyzes key milestones in the clinical implementation of iodine-131 - from the pioneering experiments of Hertz and Seidlin in the United States in 1937 to the widespread adoption of the method in the USSR beginning in the 1950s and its subsequent advancement at the National Medical Research Center for Endocrinology of the Ministry of Health of the Russian Federation. The reviewed literature highlights the significant contributions of Russian researchers to the formation of personalized theranostic approaches and underscores the need for further improvement in planning methods, dynamic treatment monitoring, and the broader expansion of radionuclide therapies for thyroid diseases.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"4-8"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pituitary adenomas: a pathway to understanding the aggressive form. Clinical genetic analysis of potential prognostic markers in the development of aggressive pituitary adenomas]. 垂体腺瘤:了解其侵袭性形式的途径。侵袭性垂体腺瘤发展中潜在预后标志物的临床遗传分析。
Pub Date : 2025-09-14 DOI: 10.14341/probl13487
Z Y Khalimova, O T Azimova

Background: Currently, due to the lack of clear criteria for predicting the aggressive course of pituitary adenomas (APA), the search for diagnostic markers is highly relevant. Genetic markers, among others, may serve as such markers since their identification is possible at early stages of the pathological process.

Objective: To study the prevalence of genotypic polymorphisms G634C of the VEGFA gene (locus rs2010963), C/T of the TP53_2 gene (locus rs17884159), C/T of the HIF1A gene (locus rs11549465), and G-197A of the IL-17A gene in a sample of patients with APA and their association with the development of various clinical variants of the aggressive course of the disease.

Materials and methods: The study included 100 patients with a clinically confirmed diagnosis of pituitary adenoma (main group) and 83 practically healthy individuals (control group). The polymorphism of the studied genes was analyzed using allele-specific polymerase chain reaction (PCR) with SNP-Express reagent kits in real-time mode ("Sintol", Russia). The interpretation of the results was carried out using the "RotorGene" software of the PCR-RV device. The study also included general clinical, biochemical, and hormonal tests, as well as instrumental and neuroimaging methods, including magnetic resonance imaging (MRI) of the chiasmatic-sellar region and statistical analysis.

Results: The study showed that the heterozygous mutation (G/C) of the G634C VEGFA polymorphism was recorded in 21 cases (26%), and the homozygous mutation with a complete replacement of guanine (G) by cysteine (C) at position 634 (C/C) was detected in 4 cases. In patients with invasive pituitary adenomas (PA), the heterozygous variant (G/C) was twice as frequent - 32.7% (n=17) compared to the control group - 15.7% (n=13). The homozygous genotype (C/C) was also more frequently observed in patients with invasive PA growth - 7.7% (n=4) compared to the control group.The heterozygous variant (C/T) of the HIF1A gene was significantly more common (p=0.02) in patients with invasive adenomas compared to the control group: 25% (n=13) and 9.8% (n=8), respectively. In non-invasive PAs, this genotype was observed three times less frequently. The study of TP53_2 polymorphism (locus rs17884159) showed that in patients with invasive PAs, the frequency of the heterozygous variant (C/T) was significantly higher - 15.4% (n=8) compared to the control group - 4.8% (n=4).

Conclusion: The conducted genetic analysis of polymorphisms in the VEGFA, HIF1A, TP53_2, and IL-17A genes revealed significant deviations, confirming their practical significance in the early diagnosis of aggressive pituitary adenomas.

背景:目前,由于缺乏明确的标准来预测垂体腺瘤(APA)的侵袭性进程,寻找诊断标志物是高度相关的。遗传标记,除其他外,可以作为这样的标记,因为它们的识别是可能的,在病理过程的早期阶段。目的:研究APA患者中VEGFA基因G634C(位点rs2010963)、TP53_2基因C/T(位点rs17884159)、HIF1A基因C/T(位点rs11549465)、IL-17A基因G-197A的基因型多态性及其与侵袭性病程中各种临床变异的关系。材料与方法:本研究纳入临床确诊垂体腺瘤患者100例(主组)和实际健康个体83例(对照组)。采用实时模式(“Sintol”,俄罗斯)的SNP-Express试剂盒,采用等位基因特异性聚合酶链反应(PCR)分析所研究基因的多态性。使用PCR-RV装置的“RotorGene”软件对结果进行解释。该研究还包括一般临床,生化和激素测试,以及仪器和神经影像学方法,包括交叉鞍区磁共振成像(MRI)和统计分析。结果:研究发现21例(26%)出现G634C VEGFA多态性杂合突变(G/C), 4例在634位点(C/C)出现鸟嘌呤(G)完全被半胱氨酸(C)取代的纯合突变。在侵袭性垂体腺瘤(PA)患者中,杂合变异(G/C)的发生率为32.7% (n=17),是对照组15.7% (n=13)的两倍。纯合子基因型(C/C)在侵袭性PA生长的患者中也更常见,与对照组相比为7.7% (n=4)。HIF1A基因杂合变异(C/T)在侵袭性腺瘤患者中比对照组更常见(p=0.02):分别为25% (n=13)和9.8% (n=8)。在非侵入性PAs中,这种基因型的出现频率要低三倍。TP53_2多态性(位点rs17884159)研究显示,侵袭性PAs患者的杂合变异(C/T)频率为15.4% (n=8),显著高于对照组的4.8% (n=4)。结论:通过对VEGFA、HIF1A、TP53_2、IL-17A基因多态性的遗传分析,发现了明显的变异,证实了其在侵袭性垂体腺瘤早期诊断中的实际意义。
{"title":"[Pituitary adenomas: a pathway to understanding the aggressive form. Clinical genetic analysis of potential prognostic markers in the development of aggressive pituitary adenomas].","authors":"Z Y Khalimova, O T Azimova","doi":"10.14341/probl13487","DOIUrl":"10.14341/probl13487","url":null,"abstract":"<p><strong>Background: </strong>Currently, due to the lack of clear criteria for predicting the aggressive course of pituitary adenomas (APA), the search for diagnostic markers is highly relevant. Genetic markers, among others, may serve as such markers since their identification is possible at early stages of the pathological process.</p><p><strong>Objective: </strong>To study the prevalence of genotypic polymorphisms G634C of the VEGFA gene (locus rs2010963), C/T of the TP53_2 gene (locus rs17884159), C/T of the HIF1A gene (locus rs11549465), and G-197A of the IL-17A gene in a sample of patients with APA and their association with the development of various clinical variants of the aggressive course of the disease.</p><p><strong>Materials and methods: </strong>The study included 100 patients with a clinically confirmed diagnosis of pituitary adenoma (main group) and 83 practically healthy individuals (control group). The polymorphism of the studied genes was analyzed using allele-specific polymerase chain reaction (PCR) with SNP-Express reagent kits in real-time mode (\"Sintol\", Russia). The interpretation of the results was carried out using the \"RotorGene\" software of the PCR-RV device. The study also included general clinical, biochemical, and hormonal tests, as well as instrumental and neuroimaging methods, including magnetic resonance imaging (MRI) of the chiasmatic-sellar region and statistical analysis.</p><p><strong>Results: </strong>The study showed that the heterozygous mutation (G/C) of the G634C VEGFA polymorphism was recorded in 21 cases (26%), and the homozygous mutation with a complete replacement of guanine (G) by cysteine (C) at position 634 (C/C) was detected in 4 cases. In patients with invasive pituitary adenomas (PA), the heterozygous variant (G/C) was twice as frequent - 32.7% (n=17) compared to the control group - 15.7% (n=13). The homozygous genotype (C/C) was also more frequently observed in patients with invasive PA growth - 7.7% (n=4) compared to the control group.The heterozygous variant (C/T) of the HIF1A gene was significantly more common (p=0.02) in patients with invasive adenomas compared to the control group: 25% (n=13) and 9.8% (n=8), respectively. In non-invasive PAs, this genotype was observed three times less frequently. The study of TP53_2 polymorphism (locus rs17884159) showed that in patients with invasive PAs, the frequency of the heterozygous variant (C/T) was significantly higher - 15.4% (n=8) compared to the control group - 4.8% (n=4).</p><p><strong>Conclusion: </strong>The conducted genetic analysis of polymorphisms in the VEGFA, HIF1A, TP53_2, and IL-17A genes revealed significant deviations, confirming their practical significance in the early diagnosis of aggressive pituitary adenomas.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"9-15"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Restoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism]. [雄激素替代和性腺功能减退联合治疗后射精质量的恢复]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13545
E R Rozhivanova, R V Rozhivanov, E N Andreeva, G А Mel'nichenko, N G Mokrysheva

Background: To optimize androgen replacement therapy for male hypogonadism to improve reproductive prospects.

Aim: To compare the effectiveness of restoring the quality of ejaculate in men receiving androgen replacement therapy (AZT) and patients receiving course combination therapy with testosterone and chorionic gonadotropin (AZT/HG).

Materials and methods: In observational prospective study was included 53 men observed at The National Medical Research Center for Endocrinology and AZT (n=19) or AZT/HG (n=34) more than 5 years, followed by stimulating gonadotropin therapy. The qualitative parameters of ejaculate were evaluated in all patients. The basic level of statistical significance was p<0,05.

Results: The patient groups were comparable in age, BMI, duration of therapy used, type of testosterone preparation, as well as the etiology of hypogonadism. Sperm concentration in the AZT group there was a statistically significant negative dynamics, while in the ART/HG group, there were no statistically significant differences in the dynamics of sperm concentration. Statistically significant differences in the value of sperm concentration change were revealed. In both groups was observed statistically significant negative dynamics for sperm motility and morphology. There were no statistically significant differences in the value of changes motility and sperm morphology in both studied groups.

Conclusion: Course combination therapy with testosterone and chorionic gonadotropin is characterized by better results for sperm concentration restoration compared with androgenic replacement therapy. For the restoration of sperm motility and morphology both methods do not show satisfactory results.

背景:优化男性性腺功能减退的雄激素替代疗法,以改善生殖前景。目的:比较雄激素替代疗法(AZT)与绒毛膜促性腺激素(AZT/HG)联合治疗对恢复男性射精质量的效果。材料和方法:观察性前瞻性研究纳入53名男性,在国家内分泌医学研究中心观察5年以上,AZT (n=19)或AZT/HG (n=34),随后刺激促性腺激素治疗。对所有患者的射精质量参数进行评价。差异有统计学意义的基本水平为p<;0,05。结果:两组患者在年龄、BMI、治疗持续时间、睾酮制剂类型以及性腺功能减退的病因方面具有可比性。AZT组精子浓度呈负动态变化,差异有统计学意义,ART/HG组精子浓度变化无统计学意义。精子浓度变化值差异有统计学意义。两组在精子活力和形态上均观察到统计学上显著的负动态。两组精子活力和形态变化值差异无统计学意义。结论:与雄激素替代治疗相比,睾酮与绒毛膜促性腺激素联合治疗在精子浓度恢复方面效果更好。对于精子活力和形态的恢复,两种方法的效果都不理想。
{"title":"[Restoration of ejaculate quality following androgen replacement and combined therapy for hypogonadism].","authors":"E R Rozhivanova, R V Rozhivanov, E N Andreeva, G А Mel'nichenko, N G Mokrysheva","doi":"10.14341/probl13545","DOIUrl":"10.14341/probl13545","url":null,"abstract":"<p><strong>Background: </strong>To optimize androgen replacement therapy for male hypogonadism to improve reproductive prospects.</p><p><strong>Aim: </strong>To compare the effectiveness of restoring the quality of ejaculate in men receiving androgen replacement therapy (AZT) and patients receiving course combination therapy with testosterone and chorionic gonadotropin (AZT/HG).</p><p><strong>Materials and methods: </strong>In observational prospective study was included 53 men observed at The National Medical Research Center for Endocrinology and AZT (n=19) or AZT/HG (n=34) more than 5 years, followed by stimulating gonadotropin therapy. The qualitative parameters of ejaculate were evaluated in all patients. The basic level of statistical significance was p&lt;0,05.</p><p><strong>Results: </strong>The patient groups were comparable in age, BMI, duration of therapy used, type of testosterone preparation, as well as the etiology of hypogonadism. Sperm concentration in the AZT group there was a statistically significant negative dynamics, while in the ART/HG group, there were no statistically significant differences in the dynamics of sperm concentration. Statistically significant differences in the value of sperm concentration change were revealed. In both groups was observed statistically significant negative dynamics for sperm motility and morphology. There were no statistically significant differences in the value of changes motility and sperm morphology in both studied groups.</p><p><strong>Conclusion: </strong>Course combination therapy with testosterone and chorionic gonadotropin is characterized by better results for sperm concentration restoration compared with androgenic replacement therapy. For the restoration of sperm motility and morphology both methods do not show satisfactory results.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"77-82"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Interchangeability of different indirect methods for determining body composition]. [测定身体成分的不同间接方法的互换性]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13538
E A Bondareva, B A Garasko, N N Khromov-Borisov, N V Mazurina, E V Ershova, K A Komshilova, E A Troshina

Background: Determination of body composition components - muscle and fat mass - is an important step in clinical and epidemiological studies. The most common methods for quantitative determination of body composition are indirect methods. However, the variety of methods and models of devices used makes direct comparison of data at both group and individual levels difficult.

Aim: The aim of the study is to analyze the consistency of estimates of absolute values of fat and lean body mass, as well as the proportion of body fat mass, obtained using bioimpedance analyzers ABC-02 «Medas» (STC Medas, Russia), 770InBody (InBody, Korea) and ultrasound scanner BodyMetrix BX2000 (IntelaMetrix, USA) in a group of men and women.

Materials and methods: An observational, single-center, cross-sectional, uncontrolled study was conducted. The main anthropometric characteristics (height and weight, waist circumference) were measured. Body composition was determined by bioimpedancemetry (BIA) using the octopolar scheme on the 770InBody device and the tetrapolar scheme on the ABC-02 Medass device and ultrasound scanning using the BodyMetrix BX2000 (BM) ultrasound scanner. The absolute (FM) and relative amount of body fat (PBF) and lean body mass were calculated.

Results: A total of 48 people (38 women and 10 men) aged 24 to 74 years were examined. The anthropometric characteristics of the examined subjects were presented in a wide range. A strong correlation was found for all pairs of body composition components: the minimum value for the pair PBF ABC-BM was 0.853 [0.730, 0.913], the maximum was 0.988 [0.977, 0.993] for the pair FM ABC-InBody. Also, significant statistical differences (p<0.001) were found for all pairs of measurements, except for PBF determined by the BIA method. High agreement (CCC>0.95) of BIA estimates of the absolute amount of fat mass was shown, moderate agreement (CCC 0.9-0.95) is characteristic of the PBF determined by different BIA analyzers, and for all other pairs the agreement of measurements can be assessed as weak (CCC<0.90).

Conclusion: The best agreement at the group and individual levels was found for FM estimates by two different BIA analyzers (InBody and ABC).

背景:测定身体组成成分——肌肉和脂肪量——是临床和流行病学研究的重要步骤。定量测定体成分最常用的方法是间接法。然而,所使用的各种方法和设备模型使得在群体和个人层面上对数据进行直接比较变得困难。目的:本研究的目的是分析在一组男性和女性中使用生物阻抗分析仪ABC-02«Medas»(STC Medas,俄罗斯),770InBody (InBody,韩国)和超声波扫描仪BodyMetrix BX2000 (IntelaMetrix,美国)获得的脂肪和瘦体重绝对值估计值以及身体脂肪质量比例的一致性。材料和方法:进行了一项观察性、单中心、横断面、非对照研究。测量主要的人体测量特征(身高、体重、腰围)。采用生物阻抗法(BIA)测定人体组成,770InBody装置采用八极结构,ABC-02 Medass装置采用四极结构,BodyMetrix BX2000 (BM)超声扫描仪进行超声扫描。计算绝对体脂量(FM)、相对体脂量(PBF)和瘦体重。结果:共检查48例,其中女性38例,男性10例,年龄24 ~ 74岁。研究对象的人体测量特征呈现在一个广泛的范围内。各对体组成成分之间均存在较强的相关性:PBF - ABC-BM对最小值为0.853 [0.730,0.913],FM - ABC-InBody对最大值为0.988[0.977,0.993]。此外,除BIA法测定的PBF外,所有测量对均发现显著的统计学差异(p<0.001)。BIA估计的绝对脂肪量显示出高一致性(CCC>0.95),中等一致性(CCC>0.95)是不同BIA分析仪确定的PBF的特征,对于所有其他对测量的一致性可以评估为弱(CCC> 0.90)。结论:两种不同的BIA分析仪(InBody和ABC)对FM的估计在群体和个人水平上是最一致的。
{"title":"[Interchangeability of different indirect methods for determining body composition].","authors":"E A Bondareva, B A Garasko, N N Khromov-Borisov, N V Mazurina, E V Ershova, K A Komshilova, E A Troshina","doi":"10.14341/probl13538","DOIUrl":"10.14341/probl13538","url":null,"abstract":"<p><strong>Background: </strong>Determination of body composition components - muscle and fat mass - is an important step in clinical and epidemiological studies. The most common methods for quantitative determination of body composition are indirect methods. However, the variety of methods and models of devices used makes direct comparison of data at both group and individual levels difficult.</p><p><strong>Aim: </strong>The aim of the study is to analyze the consistency of estimates of absolute values of fat and lean body mass, as well as the proportion of body fat mass, obtained using bioimpedance analyzers ABC-02 «Medas» (STC Medas, Russia), 770InBody (InBody, Korea) and ultrasound scanner BodyMetrix BX2000 (IntelaMetrix, USA) in a group of men and women.</p><p><strong>Materials and methods: </strong>An observational, single-center, cross-sectional, uncontrolled study was conducted. The main anthropometric characteristics (height and weight, waist circumference) were measured. Body composition was determined by bioimpedancemetry (BIA) using the octopolar scheme on the 770InBody device and the tetrapolar scheme on the ABC-02 Medass device and ultrasound scanning using the BodyMetrix BX2000 (BM) ultrasound scanner. The absolute (FM) and relative amount of body fat (PBF) and lean body mass were calculated.</p><p><strong>Results: </strong>A total of 48 people (38 women and 10 men) aged 24 to 74 years were examined. The anthropometric characteristics of the examined subjects were presented in a wide range. A strong correlation was found for all pairs of body composition components: the minimum value for the pair PBF ABC-BM was 0.853 [0.730, 0.913], the maximum was 0.988 [0.977, 0.993] for the pair FM ABC-InBody. Also, significant statistical differences (p&lt;0.001) were found for all pairs of measurements, except for PBF determined by the BIA method. High agreement (CCC&gt;0.95) of BIA estimates of the absolute amount of fat mass was shown, moderate agreement (CCC 0.9-0.95) is characteristic of the PBF determined by different BIA analyzers, and for all other pairs the agreement of measurements can be assessed as weak (CCC&lt;0.90).</p><p><strong>Conclusion: </strong>The best agreement at the group and individual levels was found for FM estimates by two different BIA analyzers (InBody and ABC).</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"47-56"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effect of preoperative bisphosphonate therapy on bone mineral density in patients with primary hyperparathyroidism one year after parathyroidectomy]. [术前双膦酸盐治疗对甲状旁腺切除术后1年原发性甲状旁腺功能亢进症患者骨密度的影响]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13574
A P Pershina-Miliutina, A K Eremkina, I D Ozhimalov, А V Khairieva, A M Gorbacheva, S V Ronzhina, N G Mokrysheva

Background: The main treatment for primary hyperparathyroidism (PHPT) is parathyroidectomy (PTE), conservative therapy, including bisphosphonates, can be used for preoperative correction of hypercalcemia, as well as to improve bone tissue condition among individuals for whom surgery should be postponed or cannot be performed due to high perioperative risks. The question of the effect of bisphosphonates on bone tissue after surgery remains open.

Aim: To study the effect of preoperative bisphosphonate therapy on BMD parameters assessed in DXA and 3D-DXA in patients with PHPT one year after radical PTE.

Materials and methods: The study was conducted on the basis of the Department of pathology of the parathyroid glands and disorders of mineral metabolism of "Endocrinology Research Center" state-funded research facility of the Ministry of Health of the Russian Federation. The study included 50 patients (2 men, 48 women), divided into two groups depending on the presence or absence of preoperative bisphosphonate (BF) therapy. The methods of DXA and 3D-DXA using 3D-Shaper Medical software were used to evaluate BMD and bone microarchitectonics. The statistical analysis was performed using the R language and the Statistica v.13 package.

Results: At the time of the disease's manifestation, both groups were comparable in terms of the main indicators of calcium phosphorus metabolism, with the exception of the level of beta-crosslapse, which was higher in the group without preoperative BPh therapy (p<0,001). There were also no differences in the parameters of DXA and 3D-DXA. After surgery, both groups showed a comparable increase in BMD based on the results of DXA in the main parts of the skeleton and 3D-DXA in the femur. Changes at the level of the statistical trend were obtained for the 3D-DXA parameters, the final absolute values of which were slightly higher in the second group, including the thickness of the cortical layer in the femur as a whole and in the neck. When comparing the results of DXA before and after PTE in patients receiving BPh, statistically significant differences in absolute BMD values were obtained only in the lumbar spine (p<0,001).According to 3D-DXA data, statistically significant differences were found only in the volume of mineral density of the trabecular bone of the femur as a whole (p=0,001).When analyzing up to - in the second group, statistically significant differences in absolute BMD values were observed in the lumbar region (p<0,001), in the hip as a whole (p<0,001) and in its neck (p=0,001).According to 3D-DXA data, statistically significant differences were found in three of the eight analyzed indicators, the volume of mineral density of the trabecular bone of the femur as a whole and in the neck (p<0,001 for both), as well as the volume of mineral density of the cortical bone in the neck, (p=0,001).

Conc

背景:原发性甲状旁腺功能亢进症(PHPT)的主要治疗方法是甲状旁腺切除术(PTE),保守治疗,包括双膦酸盐,可用于术前纠正高钙血症,以及改善因围手术期高风险而应推迟或不能进行手术的个体的骨组织状况。手术后双膦酸盐对骨组织的影响仍然是一个悬而未决的问题。目的:研究术前双膦酸盐治疗对根治性pte术后1年PHPT患者DXA和3D-DXA评估的BMD参数的影响。材料和方法:本研究由俄罗斯联邦卫生部“内分泌研究中心”国家资助研究机构甲状旁腺和矿物质代谢紊乱病理学系进行。该研究包括50例患者(2男,48女),根据术前是否使用双膦酸盐(BF)治疗分为两组。采用3D-Shaper Medical软件的DXA和3D-DXA方法评估骨密度和骨微结构。统计分析使用R语言和Statistica v.13软件包进行。结果:在疾病表现时,两组在钙磷代谢的主要指标上具有可比较性,但β -交联水平在术前未接受BPh治疗的组中较高(p< 0.001)。DXA和3D-DXA的参数也无差异。手术后,根据骨骼主要部位的DXA和股骨的3D-DXA结果,两组的骨密度都有相当的增加。3D-DXA参数在统计趋势水平上的变化,第二组的最终绝对值略高,包括股骨整体和颈部皮质层厚度。当比较BPh患者PTE前后的DXA结果时,只有腰椎的绝对BMD值有统计学意义(p< 0.001)。根据3D-DXA数据,仅在整个股骨小梁的矿物密度体积上发现有统计学意义(p= 0.001)。在第二组中,在腰椎区域(p< 0.001)、整个髋关节(p< 0.001)和颈部(p= 0.001)的绝对骨密度值上观察到统计学上的显著差异。根据3D-DXA数据,在分析的8个指标中,股骨小梁整体和颈部的矿物密度体积(p= 0.001)以及颈部皮质骨的矿物密度体积(p= 0.001)中有3个指标存在统计学差异,差异有统计学意义。结论:3D-DXA方法不仅可以评估骨密度,还可以评估其微结构,这对于预测PHPT患者的骨折风险具有重要意义。研究表明术前BPh治疗会对PTE后骨密度的恢复产生负面影响,尤其是皮质骨组织。需要进一步的研究来证实这些数据,并阐明CF对PHPT术后病程的影响。
{"title":"[Effect of preoperative bisphosphonate therapy on bone mineral density in patients with primary hyperparathyroidism one year after parathyroidectomy].","authors":"A P Pershina-Miliutina, A K Eremkina, I D Ozhimalov, А V Khairieva, A M Gorbacheva, S V Ronzhina, N G Mokrysheva","doi":"10.14341/probl13574","DOIUrl":"10.14341/probl13574","url":null,"abstract":"<p><strong>Background: </strong>The main treatment for primary hyperparathyroidism (PHPT) is parathyroidectomy (PTE), conservative therapy, including bisphosphonates, can be used for preoperative correction of hypercalcemia, as well as to improve bone tissue condition among individuals for whom surgery should be postponed or cannot be performed due to high perioperative risks. The question of the effect of bisphosphonates on bone tissue after surgery remains open.</p><p><strong>Aim: </strong>To study the effect of preoperative bisphosphonate therapy on BMD parameters assessed in DXA and 3D-DXA in patients with PHPT one year after radical PTE.</p><p><strong>Materials and methods: </strong>The study was conducted on the basis of the Department of pathology of the parathyroid glands and disorders of mineral metabolism of \"Endocrinology Research Center\" state-funded research facility of the Ministry of Health of the Russian Federation. The study included 50 patients (2 men, 48 women), divided into two groups depending on the presence or absence of preoperative bisphosphonate (BF) therapy. The methods of DXA and 3D-DXA using 3D-Shaper Medical software were used to evaluate BMD and bone microarchitectonics. The statistical analysis was performed using the R language and the Statistica v.13 package.</p><p><strong>Results: </strong>At the time of the disease's manifestation, both groups were comparable in terms of the main indicators of calcium phosphorus metabolism, with the exception of the level of beta-crosslapse, which was higher in the group without preoperative BPh therapy (p&lt;0,001). There were also no differences in the parameters of DXA and 3D-DXA. After surgery, both groups showed a comparable increase in BMD based on the results of DXA in the main parts of the skeleton and 3D-DXA in the femur. Changes at the level of the statistical trend were obtained for the 3D-DXA parameters, the final absolute values of which were slightly higher in the second group, including the thickness of the cortical layer in the femur as a whole and in the neck. When comparing the results of DXA before and after PTE in patients receiving BPh, statistically significant differences in absolute BMD values were obtained only in the lumbar spine (p&lt;0,001).According to 3D-DXA data, statistically significant differences were found only in the volume of mineral density of the trabecular bone of the femur as a whole (p=0,001).When analyzing up to - in the second group, statistically significant differences in absolute BMD values were observed in the lumbar region (p&lt;0,001), in the hip as a whole (p&lt;0,001) and in its neck (p=0,001).According to 3D-DXA data, statistically significant differences were found in three of the eight analyzed indicators, the volume of mineral density of the trabecular bone of the femur as a whole and in the neck (p&lt;0,001 for both), as well as the volume of mineral density of the cortical bone in the neck, (p=0,001).</p><p><strong>Conc","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"57-70"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Healthy longevity of women: what can a gynecologist do?] 女性的健康长寿:妇科医生能做些什么?]
Pub Date : 2025-09-14 DOI: 10.14341/probl13644
E N Andreeva, E V Sheremetyeva, O R Grigoryan

A woman spends more than a third of her life in a state of deficiency of female sex hormones. According to WHO, in most countries of the world the life expectancy of women after 50 years fluctuates between 27 and 32 years. Every year the number of women entering the menopause period increases. In 1990, 467 million were in the postmenopause period, by 2030 the number will reach 1.2 billion. Menopause, not being a disease itself, leads to a violation of the endocrine balance in the body, causing not only «classic» problems in life (vasomotor symptoms, psychological health disorders, urogenital disorders, osteoporosis, cardiovascular diseases), but also changes the appearance of women - the dermatological status of the patient is worse than the age group. The article presents modern data on rational MHT. Particular attention is paid to the issues of efficacy, tolerability and safety of combined MHT containing estrogen and gestagen, based on the results of current studies and in accordance with the position of national and international clinical guidelines. A clinical case is used to demonstrate the tactics of managing a woman in menopause.

女性一生中有三分之一以上的时间处于女性性激素缺乏的状态。据卫生组织称,在世界上大多数国家,50岁以后妇女的预期寿命在27岁至32岁之间波动。每年进入更年期的妇女人数都在增加。1990年有4.67亿人处于绝经后期,到2030年这一数字将达到12亿。更年期本身并不是一种疾病,但它破坏了体内的内分泌平衡,不仅造成了生活中的“经典”问题(血管舒缩症状、心理健康障碍、泌尿生殖系统障碍、骨质疏松症、心血管疾病),而且还改变了女性的外貌——患者的皮肤病状况比同龄人更糟。本文介绍了理性MHT的现代数据。根据目前的研究结果以及国家和国际临床指南的立场,特别关注含有雌激素和孕激素的联合MHT的疗效、耐受性和安全性问题。一个临床案例是用来证明管理一个妇女在更年期的策略。
{"title":"[Healthy longevity of women: what can a gynecologist do?]","authors":"E N Andreeva, E V Sheremetyeva, O R Grigoryan","doi":"10.14341/probl13644","DOIUrl":"10.14341/probl13644","url":null,"abstract":"<p><p>A woman spends more than a third of her life in a state of deficiency of female sex hormones. According to WHO, in most countries of the world the life expectancy of women after 50 years fluctuates between 27 and 32 years. Every year the number of women entering the menopause period increases. In 1990, 467 million were in the postmenopause period, by 2030 the number will reach 1.2 billion. Menopause, not being a disease itself, leads to a violation of the endocrine balance in the body, causing not only «classic» problems in life (vasomotor symptoms, psychological health disorders, urogenital disorders, osteoporosis, cardiovascular diseases), but also changes the appearance of women - the dermatological status of the patient is worse than the age group. The article presents modern data on rational MHT. Particular attention is paid to the issues of efficacy, tolerability and safety of combined MHT containing estrogen and gestagen, based on the results of current studies and in accordance with the position of national and international clinical guidelines. A clinical case is used to demonstrate the tactics of managing a woman in menopause.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"95-102"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cushing's disease in a 15-year-old boy, manifesting in prepubertal age]. [15岁男孩的库欣氏病,在青春期前表现出来]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13547
Y L Skorodok, I Y Ioffe, E V Plotnikova, N Y Kalinchenko, I I Nagornaya, A V Kozhevnikova, N V Kazachenko, O V Filippova

Cushing's disease (CD) is the leading form (75-80%) of the endogenous hypercortisolism (EH) in adolescents. Despite the obvious clinical manifestations, the diagnosis of CD is complicated because of the need of several research methods, the risk of false-positive and false-negative results, difficulties in interpretation and the low percentage of MR-imaging in children. The present patient had noted excessive weight gain since the age of 10 years, a decrease in growth rate was detected retrospectively, absolute short stature developed by the age of 14.5 years. An examination at the age of 15 revealed an inversion of the circadian cortisol rhythm (9:00 378.4 nmol/l, 23:00 598.9 nmol/l), an increase in the cortisol level in saliva at 23:00 (20.32 nmol/l) and excretion in urine (981.5 mcg/day). The overnight dexamethasone test (ODT) was positive (cortisol 44.26 nmol/l), ACTH was in the "gray zone" (22.19 pg/ml). MRI with contrast showed signs of a heterogeneous pituitary gland structure. When patient was re-examined at 15.5 years the inversion of the circadian rhythm of cortisol was accompanied by absolute hypercortisolemia (9:00 843.4 nmol/l, 23:00 929.4 nmol/l), ODT became negative (cortisol 235 nmol/l), ACTH level remained in the "gray zone" (25.1 pg/ml). MRI with contrast showed pituitary adenoma 6×4 mm. An ACTH level gradient between the left inferior petrosal sinus and peripheral blood of 13.3 confirmed CD. After transsphenoidal adenomectomy, a cortisol level of 39.4 nmol/l indicated remission with a low risk of relapse; subsequently a reverse development of EH symptoms were noted. Postoperative diabetes insipidus and primary hypothyroidism required replacement therapy.

库欣病(CD)是青少年内源性高皮质醇症(EH)的主要形式(75-80%)。尽管临床表现明显,但由于需要多种研究方法,假阳性和假阴性结果的风险,解释困难以及儿童mr成像比例低,CD的诊断比较复杂。本例患者自10岁起体重过度增加,回顾性发现生长速度下降,14.5岁时出现绝对身材矮小。15岁时的检查显示昼夜皮质醇节律反转(9:00 378.4 nmol/l, 23:00 598.9 nmol/l), 23:00唾液皮质醇水平升高(20.32 nmol/l),尿液皮质醇水平升高(981.5 mcg/天)。夜间地塞米松试验(ODT)阳性(皮质醇44.26 nmol/l), ACTH处于“灰色地带”(22.19 pg/ml)。磁共振造影显示垂体结构不均匀的征象。15.5岁复查时,患者皮质醇昼夜节律反转伴有绝对高皮质醇血症(9:00 843.4 nmol/l, 23:00 929.4 nmol/l), ODT变为阴性(皮质醇235 nmol/l), ACTH水平维持在“灰色地带”(25.1 pg/ml)。MRI示垂体腺瘤6×4 mm。左岩下窦与外周血间ACTH水平梯度为13.3,证实CD。经蝶窦腺瘤切除术后,皮质醇水平为39.4 nmol/l,表明病情缓解,复发风险低;随后注意到EH症状的反向发展。术后尿崩症和原发性甲状腺功能减退需要替代治疗。
{"title":"[Cushing's disease in a 15-year-old boy, manifesting in prepubertal age].","authors":"Y L Skorodok, I Y Ioffe, E V Plotnikova, N Y Kalinchenko, I I Nagornaya, A V Kozhevnikova, N V Kazachenko, O V Filippova","doi":"10.14341/probl13547","DOIUrl":"10.14341/probl13547","url":null,"abstract":"<p><p>Cushing's disease (CD) is the leading form (75-80%) of the endogenous hypercortisolism (EH) in adolescents. Despite the obvious clinical manifestations, the diagnosis of CD is complicated because of the need of several research methods, the risk of false-positive and false-negative results, difficulties in interpretation and the low percentage of MR-imaging in children. The present patient had noted excessive weight gain since the age of 10 years, a decrease in growth rate was detected retrospectively, absolute short stature developed by the age of 14.5 years. An examination at the age of 15 revealed an inversion of the circadian cortisol rhythm (9:00 378.4 nmol/l, 23:00 598.9 nmol/l), an increase in the cortisol level in saliva at 23:00 (20.32 nmol/l) and excretion in urine (981.5 mcg/day). The overnight dexamethasone test (ODT) was positive (cortisol 44.26 nmol/l), ACTH was in the \"gray zone\" (22.19 pg/ml). MRI with contrast showed signs of a heterogeneous pituitary gland structure. When patient was re-examined at 15.5 years the inversion of the circadian rhythm of cortisol was accompanied by absolute hypercortisolemia (9:00 843.4 nmol/l, 23:00 929.4 nmol/l), ODT became negative (cortisol 235 nmol/l), ACTH level remained in the \"gray zone\" (25.1 pg/ml). MRI with contrast showed pituitary adenoma 6×4 mm. An ACTH level gradient between the left inferior petrosal sinus and peripheral blood of 13.3 confirmed CD. After transsphenoidal adenomectomy, a cortisol level of 39.4 nmol/l indicated remission with a low risk of relapse; subsequently a reverse development of EH symptoms were noted. Postoperative diabetes insipidus and primary hypothyroidism required replacement therapy.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"71-76"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Dilated cardiomyopathy in a patient with Cushing's disease - clinical presentation, diagnosis and treatment: a case report]. [库欣病扩张型心肌病的临床表现、诊断和治疗:1例报告]。
Pub Date : 2025-09-14 DOI: 10.14341/probl13147
A B Kuznetsov, A Yа Grigoryev, V A Kuznetsov, Zh E Belaya, L Yа Rozhinskaya

Cortisol-induced dilated cardiomyopathy (CI-DCM) is a rare manifestation of endogenous hypercortisolism (EH). Optimal management of patients with CI-DCM is a major challenge due to the rarity of the pathology and the lack of expert community guidelines. This article describes a case of successful management of a patient with ACTH-secreting pituitary tumor and CI-DCM.A 44-year-old patient was hospitalized with symptoms of chronic heart failure (CHF) and EH. The diagnosis of non-ischemic myocardial damage with phenotype of DCM was verified by echocardiography and coronary angiography. According to hormonal and imaging tests, and selective blood sampling from the inferior petrosal sinuses, an ACTH-secreting pituitary adenoma was diagnosed. A transnasal transsphenoidal adenomectomy was planned. Due to the symptoms of CHF and systolo-diastolic dysfunction of the left ventricle (LV), significantly increasing the risk of adverse perioperative cardiac events, the intervention was postponed. Stabilization of the patient's condition was achieved after 4-month therapy with use of betaAB, ACEI, MRA, diuretics, and steroidogenesis inhibitors. Stabilization of the patient's condition allowed to perform transnasal transsphenoidal adenomectomy without perioperative complications, with postoperative decrease of ACTH and cortisol levels. Follow-up examinations demonstrated preservation of eucorticism, regression of CHF symptoms. progressive decrease of LV size/volumes with increase of LVEF.Cortisol hypersecretion can damage myocardium with a phenotype of DCM, with symptoms of CHF being the dominant clinical manifestation of EH. The use of betaAB, ACEI, diuretics, MRA, and steroidogenesis inhibitors is reasonable to control symptoms of CHF and prepare a patient with CI-DCM for surgical intervention. After normalization of cortisol level, regression of CHF symptoms and significant reduction of heart chamber size/volumes with increase of LVEF are noted, which allows to conclude about reversibility of pathologic cardiac remodeling.

皮质醇诱导的扩张型心肌病(CI-DCM)是内源性高皮质醇症(EH)的一种罕见表现。由于罕见的病理和缺乏专家社区指南,CI-DCM患者的最佳管理是一个主要挑战。这篇文章描述了一例成功的管理患者与acth分泌垂体瘤和CI-DCM。一名44岁患者因慢性心力衰竭(CHF)和EH症状住院。超声心动图和冠状动脉造影证实非缺血性心肌损伤伴DCM表型的诊断。根据激素和影像学检查,并从岩下窦选择性采血,诊断为垂体acth腺瘤。计划行经鼻蝶窦腺瘤切除术。由于出现CHF症状和左心室(LV)收缩-舒张功能障碍,明显增加围手术期心脏不良事件的风险,因此推迟了干预。在使用β - ab、ACEI、MRA、利尿剂和类固醇生成抑制剂治疗4个月后,患者病情稳定。患者病情稳定后可行经鼻经蝶腺瘤切除术,无围手术期并发症,术后ACTH和皮质醇水平下降。随访检查显示患者恢复良好,CHF症状消退。随着LVEF的增加,左室大小/容积逐渐减小。皮质醇高分泌可损害心肌,表现为DCM表型,以CHF症状为EH的主要临床表现。使用β - ab、ACEI、利尿剂、MRA和类固醇生成抑制剂可以合理地控制CHF症状,为CI-DCM患者进行手术干预做好准备。皮质醇水平正常化后,CHF症状消退,心室大小/容积随LVEF的增加而显著减少,由此得出病理性心脏重构的可逆性结论。
{"title":"[Dilated cardiomyopathy in a patient with Cushing's disease - clinical presentation, diagnosis and treatment: a case report].","authors":"A B Kuznetsov, A Yа Grigoryev, V A Kuznetsov, Zh E Belaya, L Yа Rozhinskaya","doi":"10.14341/probl13147","DOIUrl":"10.14341/probl13147","url":null,"abstract":"<p><p>Cortisol-induced dilated cardiomyopathy (CI-DCM) is a rare manifestation of endogenous hypercortisolism (EH). Optimal management of patients with CI-DCM is a major challenge due to the rarity of the pathology and the lack of expert community guidelines. This article describes a case of successful management of a patient with ACTH-secreting pituitary tumor and CI-DCM.A 44-year-old patient was hospitalized with symptoms of chronic heart failure (CHF) and EH. The diagnosis of non-ischemic myocardial damage with phenotype of DCM was verified by echocardiography and coronary angiography. According to hormonal and imaging tests, and selective blood sampling from the inferior petrosal sinuses, an ACTH-secreting pituitary adenoma was diagnosed. A transnasal transsphenoidal adenomectomy was planned. Due to the symptoms of CHF and systolo-diastolic dysfunction of the left ventricle (LV), significantly increasing the risk of adverse perioperative cardiac events, the intervention was postponed. Stabilization of the patient's condition was achieved after 4-month therapy with use of betaAB, ACEI, MRA, diuretics, and steroidogenesis inhibitors. Stabilization of the patient's condition allowed to perform transnasal transsphenoidal adenomectomy without perioperative complications, with postoperative decrease of ACTH and cortisol levels. Follow-up examinations demonstrated preservation of eucorticism, regression of CHF symptoms. progressive decrease of LV size/volumes with increase of LVEF.Cortisol hypersecretion can damage myocardium with a phenotype of DCM, with symptoms of CHF being the dominant clinical manifestation of EH. The use of betaAB, ACEI, diuretics, MRA, and steroidogenesis inhibitors is reasonable to control symptoms of CHF and prepare a patient with CI-DCM for surgical intervention. After normalization of cortisol level, regression of CHF symptoms and significant reduction of heart chamber size/volumes with increase of LVEF are noted, which allows to conclude about reversibility of pathologic cardiac remodeling.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 4","pages":"16-28"},"PeriodicalIF":0.0,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Microcephalic osteodysplastic primordial dwarfism type II (MOPD II): clinical case]. [小头型成骨异常原发性侏儒症II型(MOPD II):临床一例]。
Pub Date : 2025-07-22 DOI: 10.14341/probl13517
N A Makretskaya, N Y Kalinchenko, A N Tiulpakov

Small for gestational age (SGA) refers to the size of an infant at birth, and is defined as a birth weight and/or birth length below the -2.0 SDS for the gestational age. In approximately 10% of cases, SGA is not compensated for in the postnatal period, with the pathogenesis of this condition being attributed to various monogenic syndromes or chromosomal abnormalities. The difficulty in making a pathogenetic diagnosis in this group of patients is due, on the one hand, to the similarity of phenotypic manifestations in the structure of the disease, on the other hand, to the variability of clinical manifestations within a specific syndrome. Conducting various molecular genetic studies is the main method of diagnosing the form of SGA. Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is one of the most common genetic variants of SGA, with its phenotypic features including skeletal anomalies and cerebrovascular changes. The disease is caused by biallelic mutations in PCNT gene. This study presents the clinical characteristics of the first patient with microcephalic osteodysplastic primordial dwarfism type II in the Russian Federation. The nucleotide changes detected in the patient have not been previously described in the world literature.

小于胎龄(SGA)是指婴儿出生时的尺寸,定义为出生体重和/或出生长度低于胎龄的-2.0 SDS。在大约10%的病例中,SGA在产后没有得到补偿,这种情况的发病机制归因于各种单基因综合征或染色体异常。在这组患者中进行病理诊断的困难一方面是由于疾病结构中表型表现的相似性,另一方面是由于特定综合征内临床表现的可变性。进行各种分子遗传学研究是诊断SGA形式的主要方法。小头型成骨异常增生原始侏儒症II型(MOPD II)是SGA最常见的遗传变异之一,其表型特征包括骨骼异常和脑血管改变。该疾病是由PCNT基因双等位基因突变引起的。本研究介绍了俄罗斯联邦第一例小头型成骨异常原始侏儒症II型患者的临床特征。在患者中检测到的核苷酸变化在以前的世界文献中没有描述过。
{"title":"[Microcephalic osteodysplastic primordial dwarfism type II (MOPD II): clinical case].","authors":"N A Makretskaya, N Y Kalinchenko, A N Tiulpakov","doi":"10.14341/probl13517","DOIUrl":"10.14341/probl13517","url":null,"abstract":"<p><p>Small for gestational age (SGA) refers to the size of an infant at birth, and is defined as a birth weight and/or birth length below the -2.0 SDS for the gestational age. In approximately 10% of cases, SGA is not compensated for in the postnatal period, with the pathogenesis of this condition being attributed to various monogenic syndromes or chromosomal abnormalities. The difficulty in making a pathogenetic diagnosis in this group of patients is due, on the one hand, to the similarity of phenotypic manifestations in the structure of the disease, on the other hand, to the variability of clinical manifestations within a specific syndrome. Conducting various molecular genetic studies is the main method of diagnosing the form of SGA. Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is one of the most common genetic variants of SGA, with its phenotypic features including skeletal anomalies and cerebrovascular changes. The disease is caused by biallelic mutations in PCNT gene. This study presents the clinical characteristics of the first patient with microcephalic osteodysplastic primordial dwarfism type II in the Russian Federation. The nucleotide changes detected in the patient have not been previously described in the world literature.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 3","pages":"34-38"},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12319628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Problemy endokrinologii
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1